Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeEXECUTIVESDr. Monica Bertagnolli Appointed to Natera BOD: Noted Experienced Oncology Researcher

Dr. Monica Bertagnolli Appointed to Natera BOD: Noted Experienced Oncology Researcher

November 19, 2020

Dr. Monica Bertagnolli: “We are delighted to welcome Dr. Bertagnolli to our board at this exciting time in Natera’s growth,” said Steve Chapman, Natera’s Chief Executive Officer. “Her distinguished career as a leading oncology researcher and her extensive clinical experience will be instrumental in helping us execute on our vision of making bespoke MRD testing the standard of care worldwide.”

Dr. Monica Bertagnolli is currently Professor of Surgery at Harvard Medical School and Associate Surgeon in the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Her additional roles include Chair of the Board of Directors of the Association for Clinical Oncology (ASCO) and Group Chair of the Alliance for Clinical Trials in Oncology.

“Natera* has emerged as an innovative and dynamic leader in ctDNA technology,” said Dr. Bertagnolli. “I’m looking forward to contributing to the company’s success as it introduces the SignateraTM technology into clinical research and clinical practice. I believe this technology has the potential to change how oncologists practice medicine and significantly improve patient outcomes.”

In addition to several major committee and board advisory appointments, Dr. Bertagnolli serves as Chief Executive Officer of Alliance Foundation Trials, LLC, a not-for-profit organization that conducts international cancer clinical trials, and is Vice President of the Coalition of Cancer Cooperative Groups. She received her undergraduate degree in engineering from Princeton University and her medical degree from the University of Utah College of Medicine.

*Natera is a global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

ProSomnus® Sleep Technologies Adds John E. Remmers, MD, to Leadership Team

Dr. John E. Remmers will provide expert medical and strategic guidance on a range of initiatives, including research and development, regulatory clearances, company strategy, medical education, and clinical investigations.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.

Christopher Joyce Joins Miach Orthopaedics as VP & CFO

Christopher Joyce has joined as vice president and chief financial officer, and Kevin Sidow has been appointed to the company’s board of directors.

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion.

Recombinant Technologies is Raising Capital to Roll Out a Game Changing Alzheimer’s Treatment

Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted.

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

By using this website you agree to accept Medical Device News Magazine Privacy Policy